#AACR21 #DYK that @CIR_AACR publishes on how specific signaling events modulate antitumor immunity and response to therapy? See if any of these papers interest you! https://t.co/RznEMfhcJW https://t.co/7stKZJA3jj https://t.co/6acKokz09Y
ICYMI: Read here about a #bispecific #antibody that can unleash #γδTcell–mediated #AntitumorResponses against both #leukemia and #MultipleMyeloma. #CD40 #TcellEngager https://t.co/6xVGWucgkv https://t.co/MwD3up03rf
RT @CIR_AACR: Read here about a #bispecific #antibody that can unleash #γδTcell–mediated #AntitumorResponses against both #leukemia and #Mu…
Read here about a #bispecific #antibody that can unleash #γδTcell–mediated #AntitumorResponses against both #leukemia and #MultipleMyeloma. #CD40 #TcellEngager https://t.co/ZjnP9l4xHu https://t.co/r5xoTjAegY
New article: A bispecific antibody antagonizes pro-survival CD40 signaling and promotes Vγ9Vδ2 T cell-mediated antitumor responses in human B-cell malignancies. https://t.co/xmqZm0XZ9c #MMSM #MultipleMyeloma #hematology https://t.co/ta9zZNhS9L
#BispecificAntibodies are an emerging strategy for #cancer #immunotherapy being discussed at #SITC2020. These #CIR articles highlight their potential: https://t.co/kuAiZvmvgR https://t.co/w5YJA8wrhX https://t.co/0ZytAeMPMF https://t.co/R5TBfzlE5Q
Congrats to the LAVA team for the publication of exciting new data from a bispecific Vγ9Vδ2 T-cell engager directed against CD40 in Cancer Immunology Research. https://t.co/fuA1zp9poL #biotech #oncology #cancerresearch #bispecific #immunooncology #CD40